Does negative affectivity predict differential response to an SSRI versus a non-SSRI antidepressant?

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Journal of Clinical Psychiatry

• Publication date

  2014-09-25

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.4088/JCP.14m09025PMID 25295437
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Combination antidepressant therapy for major depressive disorder: speed and probability of remission.

  2014cited by this paper
• Interaction of 5-HTTLPR and a variation on the oxytocin receptor gene influences negative emotionality.

  2011cited by this paper
• Electrophysiological effects of the co-administration of escitalopram and bupropion on rat serotonin and norepinephrine neurons

  2010cited by this paper
• Stress, Depression, and Neuroplasticity: A Convergence of Mechanisms

  2008cited by this paper
• Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report.

  2008cited by this paper
• The other face of depression, reduced positive affect: the role of catecholamines in causation and cure

  2007cited by this paper
• What Clinical and Symptom Features and Comorbid Disorders Characterize Outpatients with Anxious Major Depressive Disorder: A Replication and Extension

  2006cited by this paper
• Do venlafaxine XR and paroxetine equally influence negative and positive affect?

  2005cited by this paper
• Clinical correlates and symptom patterns of anxious depression among patients with major depressive disorder in STAR*D

  2004cited by this paper
• Assessing the effects of bupropion SR on mood dimensions of depression.

  2004cited by this paper
• The Inventory of Depressive Symptomatology, Clinician Rating (IDS-C) and Self-Report (IDS-SR), and the Quick Inventory of Depressive Symptomatology, Clinician Rating (QIDS-C) and Self-Report (QIDS-SR) in public sector patients with mood disorders: a psychometric evaluation

  2004cited by this paper
• Defining Anxious Depression: Going beyond Comorbidity

  2003cited by this paper
• RECOGNIZING THE ANXIOUS FACE OF DEPRESSION

  2002cited by this paper
• Neurobiology of depression.

  2002cited by this paper
• Current comorbidity of psychiatric disorders among DSM-IV major depressive disorder patients in psychiatric care in the Vantaa Depression Study.

  2002cited by this paper
• Does pretreatment anxiety predict response to either bupropion SR or sertraline?

  2001cited by this paper
• Response in Relation to Baseline Anxiety Levels in Major Depressive Disorder Treated with Bupropion Sustained Release or Sertraline

  2001cited by this paper
• Can recovery from depression be achieved?

  2001cited by this paper
• Effects of sustained administration of the serotonin and norepinephrine reuptake inhibitor venlafaxine: I. in vivo electrophysiological studies in the rat.

  2000cited by this paper
• Anxiety disorders in major depression.

  2000cited by this paper
• Comorbidity of anxiety and unipolar mood disorders.

  1998cited by this paper
• Combining serotonin reuptake inhibitors and bupropion in partial responders to antidepressant monotherapy.

  1997cited by this paper
• Comorbidity of DSM–III–R Major Depressive Disorder in the General Population: Results from the US National Comorbidity Survey

  1996cited by this paper
• SSRIs in anxious‐agitated depression: a post‐hoc analysis of 279 patients

  1995cited by this paper
• Tripartite model of anxiety and depression: psychometric evidence and taxonomic implications.

  1991cited by this paper
• Coexisting depression and anxiety: special diagnostic and treatment issues.

  1991cited by this paper
• Intraindividual and interindividual analyses of positive and negative affect: their relation to health complaints, perceived stress, and daily activities.

  1988cited by this paper
• Development and validation of brief measures of positive and negative affect: the PANAS scales.

  1988cited by this paper
• Lack of efficacy of a new antidepressant (bupropion) in the treatment of panic disorder with phobias.

  1983cited by this paper
• A New Depression Scale Designed to be Sensitive to Change

  1979cited by this paper
• Assessment of social adjustment by patient self-report.

  1976cited by this paper
• A RATING SCALE FOR DEPRESSION

  1960cited by this paper

• Temperament and Depression After a First Acute Coronary Syndrome

  2019cites this paper
• The Interplay of Familial and Individual Risk in Predicting Clinical Improvements in Pediatric Anxiety Disorders

  2018cites this paper
• Anxiety, Depression, and Cardiac Outcomes After a First Diagnosis of Acute Coronary Syndrome

  2018cites this paper
• Changes in cognitive distortions and affectivity levels in adolescent depression after acute phase fluoxetine treatment

  2018cites this paper
• Efficacy and safety of escitalopram in treatment of severe depression in Chinese population

  2017cites this paper
• identifying predictive clinical characteristics of the treatment efficacy of mirtazapine monotherapy for major depressive disorder

  2016cites this paper
• Identifying predictive clinical characteristics of the treatment efficacy of mirtazapine monotherapy for major depressive disorder

  2016cites this paper
• Manipulating dopaminergic activity with bupropion : effects on reward and emotional processing biases implicated in depression

  2016cites this paper
• Bupropion: a systematic review and meta-analysis of effectiveness as an antidepressant

  2016cites this paper
• The cognitive neuropsychological model of antidepressant response

  2015cites this paper
• Risk factors for incident depression in patients at first acute coronary syndrome.

  2015cites this paper
• Treatment of maternal depression in a medication clinical trial and its effect on children.

  2015cites this paper